<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations><gtr:collaborator url="http://gtr.ukri.org:80/organisation/4DF3B36B-DFC1-41F4-BA43-548C1039E933"><gtr:id>4DF3B36B-DFC1-41F4-BA43-548C1039E933</gtr:id><gtr:name>Papworth Hospital NHS Foundation Trust</gtr:name><gtr:address><gtr:line1>Papworth Everard</gtr:line1><gtr:city>Cambridge</gtr:city><gtr:postCode>CB23 3RE</gtr:postCode><gtr:region>East Midlands</gtr:region></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/83D87776-5958-42AE-889D-B8AECF16B468"><gtr:id>83D87776-5958-42AE-889D-B8AECF16B468</gtr:id><gtr:name>University of Leeds</gtr:name><gtr:address><gtr:line1>University of Leeds</gtr:line1><gtr:line4>Leeds</gtr:line4><gtr:line5>West Yorkshire</gtr:line5><gtr:postCode>LS2 9JT</gtr:postCode><gtr:region>Yorkshire and The Humber</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/4B8017E5-40E0-4ED8-9216-7010746F9003"><gtr:id>4B8017E5-40E0-4ED8-9216-7010746F9003</gtr:id><gtr:name>Institute of Cancer Research UK</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/86BA0D2C-1895-41C5-B18C-092178DFFB3E"><gtr:id>86BA0D2C-1895-41C5-B18C-092178DFFB3E</gtr:id><gtr:name>National Institute for Health Research</gtr:name><gtr:address><gtr:line1>NIHR Clinical Research Network CC</gtr:line1><gtr:line2>Fairbairn House</gtr:line2><gtr:line3>71-75 Clarendon Road</gtr:line3><gtr:postCode>LS2 9PH</gtr:postCode><gtr:region>Yorkshire and the Humber</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/D1774113-D5D2-4B7C-A412-66A90FE4B96F"><gtr:id>D1774113-D5D2-4B7C-A412-66A90FE4B96F</gtr:id><gtr:name>University of Cambridge</gtr:name><gtr:address><gtr:line1>Lensfield Road</gtr:line1><gtr:line4>Cambridge</gtr:line4><gtr:postCode>CB2 1EW</gtr:postCode><gtr:region>East of England</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator></gtr:collaborations><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/3A5E126D-C175-4730-9B7B-E6D8CF447F83"><gtr:id>3A5E126D-C175-4730-9B7B-E6D8CF447F83</gtr:id><gtr:name>University College London</gtr:name><gtr:department>Unlisted</gtr:department><gtr:address><gtr:line1>Gower Street</gtr:line1><gtr:line4>London</gtr:line4><gtr:postCode>WC1E 6BT</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/3A5E126D-C175-4730-9B7B-E6D8CF447F83"><gtr:id>3A5E126D-C175-4730-9B7B-E6D8CF447F83</gtr:id><gtr:name>University College London</gtr:name><gtr:address><gtr:line1>Gower Street</gtr:line1><gtr:line4>London</gtr:line4><gtr:postCode>WC1E 6BT</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/4DF3B36B-DFC1-41F4-BA43-548C1039E933"><gtr:id>4DF3B36B-DFC1-41F4-BA43-548C1039E933</gtr:id><gtr:name>Papworth Hospital NHS Foundation Trust</gtr:name><gtr:address><gtr:line1>Papworth Everard</gtr:line1><gtr:city>Cambridge</gtr:city><gtr:postCode>CB23 3RE</gtr:postCode><gtr:region>East Midlands</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/83D87776-5958-42AE-889D-B8AECF16B468"><gtr:id>83D87776-5958-42AE-889D-B8AECF16B468</gtr:id><gtr:name>University of Leeds</gtr:name><gtr:address><gtr:line1>University of Leeds</gtr:line1><gtr:line4>Leeds</gtr:line4><gtr:line5>West Yorkshire</gtr:line5><gtr:postCode>LS2 9JT</gtr:postCode><gtr:region>Yorkshire and The Humber</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/4B8017E5-40E0-4ED8-9216-7010746F9003"><gtr:id>4B8017E5-40E0-4ED8-9216-7010746F9003</gtr:id><gtr:name>Institute of Cancer Research UK</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/86BA0D2C-1895-41C5-B18C-092178DFFB3E"><gtr:id>86BA0D2C-1895-41C5-B18C-092178DFFB3E</gtr:id><gtr:name>National Institute for Health Research</gtr:name><gtr:address><gtr:line1>NIHR Clinical Research Network CC</gtr:line1><gtr:line2>Fairbairn House</gtr:line2><gtr:line3>71-75 Clarendon Road</gtr:line3><gtr:postCode>LS2 9PH</gtr:postCode><gtr:region>Yorkshire and the Humber</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/D1774113-D5D2-4B7C-A412-66A90FE4B96F"><gtr:id>D1774113-D5D2-4B7C-A412-66A90FE4B96F</gtr:id><gtr:name>University of Cambridge</gtr:name><gtr:address><gtr:line1>Lensfield Road</gtr:line1><gtr:line4>Cambridge</gtr:line4><gtr:postCode>CB2 1EW</gtr:postCode><gtr:region>East of England</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>FELLOW</gtr:name></gtr:role><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/748BDE8D-1E1A-48FA-A835-998CC3EB179D"><gtr:id>748BDE8D-1E1A-48FA-A835-998CC3EB179D</gtr:id><gtr:firstName>Frank</gtr:firstName><gtr:surname>McCaughan</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role><gtr:role><gtr:name>FELLOW</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=G0500392"><gtr:id>29F34527-1E25-42B5-B117-D07E7830BDEF</gtr:id><gtr:title>Gene amplification within chromosome 3q in preinvasive bronchial lesions - towards targets for novel biomarkers and ther</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Fellowship</gtr:grantCategory><gtr:grantReference>G0500392</gtr:grantReference><gtr:abstractText>Lung cancer is the most common cause of death from cancer in both males and females in the United Kingdom. The survival after diagnosis is the worst of all common cancers. The main reasons for this are that patients have advanced disease when diagnosed and that currently available treatments are not very effective. New approaches are required.

We have collected a number of samples from patients? lungs with early changes known as preinvasive lesions. These may have the potential to progress to lung cancer. This collection is unique. Our preliminary analysis has shown that an area of chromosome 3 tends to be abnormal in these samples. This agrees with work from other laboratories that suggests this part of chromosome 3 is abnormal in lung cancer. We want to further characterise this abnormality and hopefully gain insights into the particular genes involved. Such genes could provide a biomarker which would predict risk of developing lung cancer. In addition the proteins coded for by these genes may be responsible for the progression of the preinvasive lesion and therefore they may represent targets suitable for new drug treatments.</gtr:abstractText><gtr:technicalSummary>Lung cancer is responsible for more deaths than any other cancer in the UK. Novel approaches to early detection and treatment are desperately required. Each tumour harbours numerous genomic aberrations including gene amplification. It is proposed that amplicons harbour oncogenes which confer a growth advantage, thereby contributing to the malignant phenotype. Such amplified oncogenes may serve as molecular biomarkers and may also be excellent targets for novel therapies. Classically genome amplification has been analysed using Comparative Genomic Hybridisation (CGH), a low resolution technique which compares the relative abundance of chromosomal regions in tumour to that of normal DNA. The host group at UCL has a unique archive consisting of serial samples of preinvasive bronchial epithelial lesions from patients enrolled in a surveillance project, giving an unrivalled opportunity to study the dynamics of squamous cell carcinoma evolution. Preliminary data from these samples, using CGH to test the whole genome, demonstrates that amplification of chromosome 3q is the most frequent genomic event in early or preinvasive lesions. The hypothesis for this project has two elements: firstly that a commonly amplified region of chromosome 3q will contain an oncogene(s) involved in the progression of preinvasive squamous lung cancer; and secondly, that amplicons will evolve with progression of preinvasive lesions. To test this I will:
1) Precisely delineate and characterise the 3q amplicon in this unique chronological series of bronchial preinvasive lesions using a novel technique - Molecular Counting by Limiting Dilution (MCLD):
2) Use genomic databases and data from 1) to identify candidate oncogene(s) within the amplicon.
We have established a collaboration with Dr P Dear (MRC-LMB Cambridge) to use MCLD to define the amplicon boundaries from each sample. Results will be compared a) from all samples to define the smallest common region of chromosome 3q amplification; and b) from sequential biopsies of specific lesions to determine if amplicons evolve with lesion progression. By interrogating genomic databases I will identify candidate oncogenes in the amplified region. Once candidate genes are identified I will consider expression and functional analyses as appropriate. It is expected that these studies will provide basic insights into the dynamics of amplicon development. Furthermore, successful identification of an oncogene involved in early lung cancer evolution may provide a novel target suitable for either development as a biomarker or, as a target for therapeutic intervention, and therefore could have implications for improving the appalling mortality associated with this condition.</gtr:technicalSummary><gtr:fund><gtr:end>2008-08-31</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2005-09-01</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>190261</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs><gtr:collaborationOutput><gtr:collaboratingOrganisation>National Institute for Health Research</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>NIHR Comprehensive Biomedical Research Centre, Guy's and St Thomas</gtr:department><gtr:description>KHP Thoracic Tissue</gtr:description><gtr:id>B42E82BB-CD1B-4D76-AE4E-E8C83D1F917D</gtr:id><gtr:impact>Publications and abstracts</gtr:impact><gtr:outcomeId>56df610582f2d6.78699435-1</gtr:outcomeId><gtr:partnerContribution>Access to specimens</gtr:partnerContribution><gtr:piContribution>This is an an active and dynamic collaboration investigating pathogenic mechanisms in lung cancer and circulating biomarkers.</gtr:piContribution><gtr:sector>Public</gtr:sector><gtr:start>2013-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Cambridge</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Department of Pathology</gtr:department><gtr:description>HAPPY Mapping Cancer Genomes</gtr:description><gtr:id>F81EDFFA-939F-423A-B280-270B5362CFA1</gtr:id><gtr:impact>Publication submitted</gtr:impact><gtr:outcomeId>237EABE7C19-1</gtr:outcomeId><gtr:partnerContribution>Application novel methodology</gtr:partnerContribution><gtr:piContribution>Technical expertise and experimental work</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2007-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Institute of Cancer Research UK</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>Multilocus integrated evaluation of CNAs and sequence mutations</gtr:description><gtr:id>3AD7835A-674F-43D7-B16F-188360434457</gtr:id><gtr:impact>Multidisciplinary - clinical teams and basic scientists</gtr:impact><gtr:outcomeId>fetrRjvHYng-1</gtr:outcomeId><gtr:partnerContribution>Supply of materialsSupply of Materials</gtr:partnerContribution><gtr:piContribution>Technique development. Application to diagnostic specimens</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2011-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Papworth Hospital NHS Foundation Trust</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>Multilocus integrated evaluation of CNAs and sequence mutations</gtr:description><gtr:id>95236B3F-9925-4CFB-84DD-56F825C53C5F</gtr:id><gtr:impact>Multidisciplinary - clinical teams and basic scientists</gtr:impact><gtr:outcomeId>fetrRjvHYng-2</gtr:outcomeId><gtr:partnerContribution>Supply of materialsSupply of Materials</gtr:partnerContribution><gtr:piContribution>Technique development. Application to diagnostic specimens</gtr:piContribution><gtr:sector>Public</gtr:sector><gtr:start>2011-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Papworth Hospital NHS Foundation Trust</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>Papworth</gtr:description><gtr:id>B6850423-9555-4350-AA68-866AE37149A7</gtr:id><gtr:impact>For next year's return - paper under review</gtr:impact><gtr:outcomeId>56df64ea670c69.27793238-1</gtr:outcomeId><gtr:partnerContribution>Papworth colleagues have contributed a tissue microarray</gtr:partnerContribution><gtr:piContribution>Biological understanding</gtr:piContribution><gtr:sector>Public</gtr:sector><gtr:start>2015-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Leeds</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Leeds Institute of Biomedical &amp; Clinical Sciences (LIBACS)</gtr:department><gtr:description>Squamous Carcinoma</gtr:description><gtr:id>58D05C74-9FF6-41D7-B460-398BFDFCA324</gtr:id><gtr:impact>Not as yet</gtr:impact><gtr:outcomeId>foeuVBwQy9Z-1</gtr:outcomeId><gtr:partnerContribution>Sample analysis</gtr:partnerContribution><gtr:piContribution>Sample supply</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Leeds</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Leeds Institute of Molecular Medicine</gtr:department><gtr:description>Re-SEARCH trial</gtr:description><gtr:id>29AE475B-9125-423F-B486-E9DF53795070</gtr:id><gtr:impact>Multicentre clinical trial now funded</gtr:impact><gtr:outcomeId>8CA2F3E8BD9-1</gtr:outcomeId><gtr:partnerContribution>Advice</gtr:partnerContribution><gtr:piContribution>Writing grant proposal</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2006-01-01</gtr:start></gtr:collaborationOutput></gtr:collaborationOutputs><gtr:disseminationOutputs/><gtr:exploitationOutputs/><gtr:furtherFundingOutputs><gtr:furtherFundingOutput><gtr:amountPounds>90000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>NC3R Studentship</gtr:description><gtr:end>2018-09-02</gtr:end><gtr:fundingOrg>National Centre for the Replacement, Refinement and Reduction of Animals in Research (NC3Rs)</gtr:fundingOrg><gtr:id>A8C6C3FD-4CC9-4349-8D48-892863962387</gtr:id><gtr:outcomeId>56df5d76a88305.59155319</gtr:outcomeId><gtr:sector>Private</gtr:sector><gtr:start>2015-10-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>141000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Roy Castle Lung Cancer Fund</gtr:description><gtr:end>2018-04-02</gtr:end><gtr:fundingOrg>Roy Castle Lung Cancer Foundation</gtr:fundingOrg><gtr:id>A7F3C142-3345-475A-86BE-BA4F769AA66F</gtr:id><gtr:outcomeId>56df5dcc47d673.59869285</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2016-06-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>875000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Wellcome Trust Intermediate Fellowship</gtr:description><gtr:end>2017-05-02</gtr:end><gtr:fundingOrg>Wellcome Trust</gtr:fundingOrg><gtr:id>9278BEF8-E789-43A3-8A08-7604D55592F2</gtr:id><gtr:outcomeId>Bu1wjL95cn6</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2012-05-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>97000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Challenge Fund</gtr:description><gtr:end>2015-04-02</gtr:end><gtr:fundingOrg>King?s Health Partners</gtr:fundingOrg><gtr:id>11C22061-F042-48CD-B7CF-0B2302B27389</gtr:id><gtr:outcomeId>CbukFTeyHye</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector><gtr:start>2014-04-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>24000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Roy Castle</gtr:description><gtr:end>2013-08-02</gtr:end><gtr:fundingOrg>Roy Castle Lung Cancer Foundation</gtr:fundingOrg><gtr:id>6D623B15-5FB4-4833-A90A-3FE2955B3E5A</gtr:id><gtr:outcomeId>Hadft1imSSD</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2013-08-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>150000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>MRC Career Development Fellowship</gtr:description><gtr:end>2012-01-02</gtr:end><gtr:fundingOrg>Medical Research Council (MRC)</gtr:fundingOrg><gtr:id>5DBBB98E-E22D-4DD0-8D3A-1EB198404C59</gtr:id><gtr:outcomeId>D1351E5DDAA0</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector><gtr:start>2010-01-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>21000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>MRCT</gtr:description><gtr:end>2012-06-02</gtr:end><gtr:fundingOrg>Medical Research Council (MRC)</gtr:fundingOrg><gtr:id>050FE5E1-0876-4175-A0DF-F4AD9EFE9F41</gtr:id><gtr:outcomeId>UAcqEhJenDh0</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector><gtr:start>2011-06-01</gtr:start></gtr:furtherFundingOutput></gtr:furtherFundingOutputs><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>ACCP guidelines</gtr:description><gtr:geographicReach>Multiple continents/international</gtr:geographicReach><gtr:guidelineTitle>Epidemiology of lung cancer: diagnosis and management of lung cancer: American College of Chest Physicians evidence-based clinical practice guidelines</gtr:guidelineTitle><gtr:id>34444A83-FA4F-4CA1-AF3F-63942F197F79</gtr:id><gtr:outcomeId>56df5f20305573.65865259</gtr:outcomeId><gtr:type>Citation in clinical guidelines</gtr:type></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Lead Lung Cancer</gtr:description><gtr:geographicReach>Local/Municipal/Regional</gtr:geographicReach><gtr:id>9500E64E-4C4B-42A0-AAC7-160B8EC80369</gtr:id><gtr:impact>Reorganised service delivery</gtr:impact><gtr:outcomeId>hFyA6LnEi5B</gtr:outcomeId><gtr:type>Influenced training of practitioners or researchers</gtr:type></gtr:policyInfluenceOutput></gtr:policyInfluenceOutputs><gtr:productOutputs><gtr:productOutput><gtr:clinicalTrial>true</gtr:clinicalTrial><gtr:description>Digital PCR for circulating nucleic acid biomarkers</gtr:description><gtr:id>FFE55E6E-8ADF-4CED-A183-84F6AAB79099</gtr:id><gtr:impact>First paper in press. Presentations at national meetings.</gtr:impact><gtr:outcomeId>TJrCnJUtswc</gtr:outcomeId><gtr:stage>Early clinical assessment</gtr:stage><gtr:status>Under active development/distribution</gtr:status><gtr:title>Circulating Tumour DNA</gtr:title><gtr:type>Diagnostic Tool - Non-Imaging</gtr:type><gtr:yearDevCompleted>2012</gtr:yearDevCompleted></gtr:productOutput></gtr:productOutputs><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs><gtr:researchMaterialOutput><gtr:description>Single molecule genomics technique</gtr:description><gtr:id>A9F0A60D-3453-4449-9F4F-D9B7EEE177B3</gtr:id><gtr:impact>Publication only to date. Others pending</gtr:impact><gtr:outcomeId>4CD66D5A5C3</gtr:outcomeId><gtr:providedToOthers>true</gtr:providedToOthers><gtr:title>Copy-number Analysis</gtr:title><gtr:type>Technology assay or reagent</gtr:type><gtr:yearFirstProvided>2009</gtr:yearFirstProvided></gtr:researchMaterialOutput></gtr:researchMaterialOutputs><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication><gtr:id>F6391B54-8605-47FB-A309-0B76788B7EDB</gtr:id><gtr:title>Assessment of Minimal Residual Disease in Standard-Risk AML.</gtr:title><gtr:parentPublicationTitle>The New England journal of medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/7157bdaf7078a36d0c29de1f4ee8f0fc"><gtr:id>7157bdaf7078a36d0c29de1f4ee8f0fc</gtr:id><gtr:otherNames>Ivey A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0028-4793</gtr:issn><gtr:outcomeId>56df5c49edc663.36916362</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>BBE08189-C7DE-4900-A78E-E4BA7F9D03EE</gtr:id><gtr:title>IRS2 is a candidate driver oncogene on 13q34 in colorectal cancer.</gtr:title><gtr:parentPublicationTitle>International journal of experimental pathology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/6642d4f073513e35e143ada71650af22"><gtr:id>6642d4f073513e35e143ada71650af22</gtr:id><gtr:otherNames>Day E</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0959-9673</gtr:issn><gtr:outcomeId>pm_16532_22_23594372</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>51C7024A-24F1-495E-A3F2-6292199249C5</gtr:id><gtr:title>Progressive 3q amplification consistently targets SOX2 in preinvasive squamous lung cancer.</gtr:title><gtr:parentPublicationTitle>American journal of respiratory and critical care medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/571a0cb275300a32e9185f4502768350"><gtr:id>571a0cb275300a32e9185f4502768350</gtr:id><gtr:otherNames>McCaughan F</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>1073-449X</gtr:issn><gtr:outcomeId>56df5caeaf4f34.23067954</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>B6C69F60-E75C-4FBD-89FB-7A0C28EDDF35</gtr:id><gtr:title>Single-molecule genomics.</gtr:title><gtr:parentPublicationTitle>The Journal of pathology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/571a0cb275300a32e9185f4502768350"><gtr:id>571a0cb275300a32e9185f4502768350</gtr:id><gtr:otherNames>McCaughan F</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0022-3417</gtr:issn><gtr:outcomeId>56df5caf00ee50.13138668</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>EAC42D16-FD6E-4E66-99B9-E80B88001E6F</gtr:id><gtr:title>Single-molecule analysis of genome rearrangements in cancer.</gtr:title><gtr:parentPublicationTitle>Nucleic acids research</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/b201495d9d323e7e841aa5cc0631c3b3"><gtr:id>b201495d9d323e7e841aa5cc0631c3b3</gtr:id><gtr:otherNames>Pole JC</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0305-1048</gtr:issn><gtr:outcomeId>56df5cae29d8e5.62093382</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>AF0F3954-084B-4047-A6A6-1578772E1AEC</gtr:id><gtr:title>Circulating DNA in solid organ cancers-analysis and clinical application.</gtr:title><gtr:parentPublicationTitle>QJM : monthly journal of the Association of Physicians</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/6097d830555e8c90cc1992b0b3b65d38"><gtr:id>6097d830555e8c90cc1992b0b3b65d38</gtr:id><gtr:otherNames>Karampini E</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1460-2393</gtr:issn><gtr:outcomeId>56df5cadc34702.99724829</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>AA2C6E7E-2CF8-4E80-A5C2-2CD131DE7CA6</gtr:id><gtr:title>Digital PCR strategies in the development and analysis of molecular biomarkers for personalized medicine.</gtr:title><gtr:parentPublicationTitle>Methods (San Diego, Calif.)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/6642d4f073513e35e143ada71650af22"><gtr:id>6642d4f073513e35e143ada71650af22</gtr:id><gtr:otherNames>Day E</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1046-2023</gtr:issn><gtr:outcomeId>pm_16532_22_22926236</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>E26CD53E-C7B3-4B30-9CF1-61A49AEC2675</gtr:id><gtr:title>Molecular copy-number counting: potential of single-molecule diagnostics.</gtr:title><gtr:parentPublicationTitle>Expert review of molecular diagnostics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/571a0cb275300a32e9185f4502768350"><gtr:id>571a0cb275300a32e9185f4502768350</gtr:id><gtr:otherNames>McCaughan F</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>1473-7159</gtr:issn><gtr:outcomeId>56df5caf24b4d2.59229604</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>29ECC022-AB17-497C-A7B3-76D35674D49B</gtr:id><gtr:title>Microdissection molecular copy-number counting (microMCC)--unlocking cancer archives with digital PCR.</gtr:title><gtr:parentPublicationTitle>The Journal of pathology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/571a0cb275300a32e9185f4502768350"><gtr:id>571a0cb275300a32e9185f4502768350</gtr:id><gtr:otherNames>McCaughan F</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>0022-3417</gtr:issn><gtr:outcomeId>56df5caf4478b2.14271718</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>5E2419D4-9728-4CF6-AA89-C1EF88164124</gtr:id><gtr:title>Cell migration leads to spatially distinct but clonally related airway cancer precursors.</gtr:title><gtr:parentPublicationTitle>Thorax</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/7ac24a3881334fcf2e7cab05404a1505"><gtr:id>7ac24a3881334fcf2e7cab05404a1505</gtr:id><gtr:otherNames>Pipinikas CP</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0040-6376</gtr:issn><gtr:outcomeId>5462026170afa9.61280486</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>06AA48C9-B03F-4E76-B94B-90DBA03288DC</gtr:id><gtr:title>Genomic evidence of pre-invasive clonal expansion, dispersal and progression in bronchial dysplasia.</gtr:title><gtr:parentPublicationTitle>The Journal of pathology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/571a0cb275300a32e9185f4502768350"><gtr:id>571a0cb275300a32e9185f4502768350</gtr:id><gtr:otherNames>McCaughan F</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0022-3417</gtr:issn><gtr:outcomeId>56df5cae7efdb9.42180675</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>1DFF089F-DF7F-46BE-8B02-684A5EECBE74</gtr:id><gtr:title>Microdroplet digital PCR: detection and quantitation of biomarkers in archived tissue and serial plasma samples in patients with lung cancer.</gtr:title><gtr:parentPublicationTitle>Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/a8e49ffed5fb0d02ad5f6ec5fce26614"><gtr:id>a8e49ffed5fb0d02ad5f6ec5fce26614</gtr:id><gtr:otherNames>Gao F</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1556-0864</gtr:issn><gtr:outcomeId>56df5cae081df2.12928332</gtr:outcomeId></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">G0500392</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>7C58A707-1BF6-4573-A44F-30B271C80813</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>Cancer</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>1BF330A9-C7B5-49C5-B54B-CF4FAE6DF1D8</gtr:id><gtr:percentage>75</gtr:percentage><gtr:text>2.1  Biological and endogenous factors</gtr:text></gtr:researchActivity><gtr:researchActivity><gtr:id>89AE580F-2437-4540-9640-37005C968E67</gtr:id><gtr:percentage>25</gtr:percentage><gtr:text>4.1  Discovery and preclinical testing of markers and technologies</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>